Streamlining Clinical Trials and Drug Discovery with AI
The drug development landscape is evolving with the introduction of Generative AI (GEN AI), offering unparalleled opportunities for innovation and efficiency. Generative AI technology uses natural language processing (NLP) to create new text from existing data.
This Axendia Market Research Report: “The State of Generative AI in Life Sciences: The Good, The Bad, the Ugly,” is presented by Certara. The information was gathered from a survey of over 200 pharmaceutical industry professionals. Additionally, technology leaders at Boehringer Ingelheim and Bristol Myers Squibb provided input.
Submit the form to download your free copy of the market research report!
Learn how GEN AI can help your organization:
-
- Enhance drug discovery: Accelerate the identification and development of new therapeutics.
-
- Streamline clinical trials: Predictive modeling for drug safety and efficacy is a leading application of this technology.
-
- Accelerate lab processes: Automate data analysis and interpretation
Why Certara?
Pharmaceutical industry AI experts developed Certara’s Gen AI platform, Certara.AI. This platform combines GenAI models pre-trained on life sciences data with a flexible data connectivity platform. Thus, this technology enables drug developers to access their organizational data in real-time. Certara.AI comprises the foundation that life science organizations need for successful Gen AI implementation.